

DIGNITANA

Clinically superior scalp cooling

NOVEMBER 17 • 2022



**Accelerated growth
and extraordinary
customer satisfaction**

Q3 22

QUARTERLY REPORT

Accelerated growth and extraordinary customer satisfaction

Financial highlights Q3 2022

- Net sales amounted to 18.6 MSEK (13.7), an increase of 36 percent over the same period in 2021.
- Operating result amounted to -3.6 MSEK (-13.6).
- Net result after financial items amounted to -3.7 MSEK (-13.9).
- Earnings per share were -0,06 SEK (-0,21).
- Cash Balance amounted to 6.7 MSEK (21.0).
- Average Daily Treatment Revenue (ADTR)* was 203 TSEK (147), an increase of 38 percent over the same period in 2021.

Business highlights during the period

- Dignitana launched the DigniCap Direct Partner Portal.
- Dignitana appointed Malin Isacson as Vice President of Sales for Europe.
- Dignitana sponsored signature fundraising events for Susan G. Komen® in Los Angeles and Hair to Stay in San Francisco.

Significant events after the period

- In October Dignitana announced a directed share issue of approximately 25 MSEK.

Business highlights after the period

- Dignitana CEO Catarina Mård Löwenadler was featured at the Aktiespararna Women's Night in Stockholm.
- Dignitana appointed Johan Johansson as VP Operations, Research and Development.

"The fact that nearly ALL Dignitana patients would recommend DigniCap to someone else is an endorsement that we are very proud to receive."

Catarina Löwenadler, CEO Dignitana AB



Key Figures

DIGNITANA GROUP	Q3 2022	Q3 2021	Q1-Q3 2022	Q1-Q3 2021	Full year 2021
Net sales, TSEK	18 602	13 657	52 750	40 860	57 073
Total revenues, TSEK	21 651	13 723	62 428	45 054	62 376
Net profit after financial items, TSEK	-3 660	-13 916	-10 400	-31 240	-43 076
Cash and bank balances, TSEK	6 737	21 047	6 737	21 047	14 501
Earnings per share before and after dilution, SEK	-0,06	-0,21	-0,16	-0,48	-0,66
Average Daily Treatment Revenue, TSEK	203	147	194	146	147

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING AND QUALITY OF LIFE FOR CANCER PATIENTS.

Awareness, accessibility, affordability, and happiness

These four words summarize the path that Dignitana has taken as we work to provide clinically superior scalp cooling to as many patients as possible.

We have a clear strategy and are now effectively executing our plan. Net sales in the period showed solid growth with a 36 percent improvement over Q3 2021 and a 38 percent improvement in Average Daily Treatment Revenue (ADTR) versus the same period one year ago. Our growth is primarily supported by increased utilization – a direct result of our focus on clinics with the potential for high patient volumes. We are ramping up in a targeted and strategic manner, even though we have had supply chain delays partly impacting our manufacturing capacities. These issues are expected to improve at the end of the year and will further support our accelerated growth together with our focus of investments in three areas: awareness, accessibility, and affordability.

Growing Awareness

As we look back to 2015 when DigniCap was the first scalp cooling device to receive FDA clearance in the United States, we see that we have come a long way in educating health care providers. The conversations with clinicians have changed. Now we typically don't need to explain what scalp cooling is or why it matters – but instead often answer questions about reimbursement, workflow, and efficacy. The medical oncology community is aware of scalp cooling – and now is the time to push them to take action to provide DigniCap to meet growing patient demand.

A significant portion of funds from the recent directed share issue will go toward marketing initiatives to further expand the awareness of DigniCap among patients and healthcare providers, with increased presence at medical conferences, nursing forums, and community-based programs with our providers and advocacy groups.

Expanding Accessibility

With the funding raised right after the close of the period we will accelerate the placement of devices in addition to the emphasis on increased utilization to give more patients access to treatment.

Our focus is on the US, along with selected markets in the EU and Japan. These are areas with high patient volume potential that can support increased utilization per device. In terms of new locations, our concentration is on horizontal expansion through the contracts we have with large provider groups, ensuring that we are optimizing key existing relationships and opportunities.



A handwritten signature in blue ink, appearing to read 'Catarina Löwenadler'.

Catarina Löwenadler, CEO Dignitana AB

Improving Affordability

We are working to improve affordability for patients in several ways, with Reimbursement at the top of the list. Earlier this year we launched a new “Buy and Bill” business model to create a pathway for providers to be reimbursed for the specialized scalp cooling service they are providing to patients. We now have several customers who are routinely filing reimbursement claims with a wide number of payers, including a large medical group in New York and other practices in the Eastern and Mid-Western regions of the US. The outcome of these claims is not yet standardized or predictable on a case-by-case basis, but we are seeing distinct progress overall with reimbursement from a wide range of payers.

Our work with advocacy groups and foundations continues to be an important component, helping to bridge the gap for many patients with financial need who are interested in using DigniCap.

Delivering Happiness

In our last Interim Report, I spoke about the passion, dedication, and experience of our team – truly putting patients first in all that we do. I am proud to say this is clearly evident in a recent patient survey which showed a customer satisfaction score of 97 percent. Especially when we consider that patients use DigniCap during a very difficult period in their lives, the fact that nearly ALL Dignitana patients would recommend DigniCap to someone else is an endorsement that we are very proud to receive.

Customer satisfaction with healthcare providers is also a primary objective. To support those efforts, in September we launched DigniCap Direct, a partner portal designed to provide one-stop access to DigniCap training, ordering and resources. The site has been enthusiastically received by our US providers and will soon be available to providers and distributors around the globe.

We are dedicated to working with clinics on all aspects of the continuum of care, improving every touch point, and continuing to deliver high customer satisfaction to both patients and providers.

Advancing forward

We have raised capital, the momentum for reimbursement is building, we have accelerated marketing activities, and we see the results of our common efforts and passionate team that is allowing us to serve more patients. It is an exciting time to be a part of Dignitana, and we appreciate the support of our shareholders in this journey.

The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and U.S. operations are based in Dallas, Texas. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.

The Company produces The DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat other solid

tumors in addition to the original indication for use by patients with breast cancer. In 2019 Dignitana introduced the next generation DigniCap Delta. The technologically advanced DigniCap Delta model received CE Marking and FDA clearance that year, as well as regulatory approvals in Australia and Israel.

Scalp cooling is recognized as standard of care by numerous organizations around the world. European Society for Medical Oncology (ESMO) added scalp cooling as a Category IIB treatment recommendation in 2020 and Cancer Australia added scalp cooling to its Fall 2020 update providing guidance for the management of early breast cancer patients. In the United States clinical recommendations introduced in 2019 and 2020 by the National Comprehensive Cancer Network® and a policy reaffirmation by the American Medical Association in 2022 all contribute to a solid foundation for scalp cooling to become standard of care in the United States.


Business model

Dignitana has two business models that each include an ongoing revenue stream from the sale of consumables.

In the United States devices are leased to providers and the Company utilizes a pay-per-treatment model. The availability of scalp cooling continues to expand as we work toward scalp cooling becoming standard of care providing access to more patients. Dignitana also offers a buy and bill model that supports reimbursement initiatives. As reimbursement and coverage become more predictable,

we anticipate providers will transition to this widely accepted business model.

Outside the U.S. devices are sold to medical facilities and the company also receives revenue from service and maintenance agreements. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



Reimbursement

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability. Health care providers are key partners in our efforts to increase accessibility to improve quality of life for as many cancer patients as possible. Dignitana recognizes that providers allocate a range of resources to scalp cooling therapy and their clinical expertise, direct patient care, and skilled operation of the DigniCap device by trained personnel ensure that DigniCap patients have the most successful clinical outcomes possible. The buy and bill model Dignitana offers facilitates a pathway for providers to be reimbursed for the specialized service they are providing to patients.

Dignitana has led the way in reimbursement efforts for scalp cooling in the U.S., including work supporting the 2021 introduction of CPT® codes for scalp cooling and a rate assignment from the Centers for Medicare & Medicaid Services (CMS) that was introduced in 2022. Dignitana continues to work with healthcare providers and payers to advance reimbursement of scalp cooling, and the Company has a Reimbursement Hub for patients to receive direct support and guidance in filing claims for reimbursement.

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors.

Globally there are over 17 million incidences of cancer diagnosed annually, with 1.9 million diagnoses occurring in the U.S. each year, and by 2040 the global cancer burden is projected to reach 28 million new incidences solely due to growth and aging of the population. In the U.S. it is estimated that 39 out of 100 women and 40 out of 100 men will develop cancer during their lifetime.

Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in the world. Globally 2.3 million cases of breast cancer are diagnosed annually, with 291,000 of those in the United States. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers. Non-breast solid tumors represent nearly one million patients in the U.S. annually.

Dignitana estimates that up to 60 percent of all cancer patients are on regimens that are compatible with DigniCap. Additionally published studies have found that 8-10% of female patients refuse chemotherapy due to concern over hair loss, and 96 percent of potential patients surveyed were interested in scalp cooling.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. DigniCap was the first scalp cooling system to receive FDA clearance, with only two other systems now on the market that received clearance more recently. The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.

To increase awareness and utilization of scalp cooling Dignitana works with patient advocacy organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this, in addition to numerous partnerships with foundations across the United States.

In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.



Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leasing of systems to health care providers, pay-per-treatment fees, service and maintenance agreements, sales of individual caps and kit accessories. For the third quarter 2022 net sales amounted to 18 602 TSEK (13 657), an increase over the same period 2021 by 4 945 TSEK representing 36 percent growth.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased to health care providers and the Company generates revenues from the leasing contracts through monthly leasing fees as well as payment for treatments and sales of products related to patient treatments. Outside the U.S, revenues are generated by sales of DigniCap Delta systems, frequently combined with service and maintenance agreements, as well as the sale of patient-related products and consumables.

The U.S. market is still the driver in placing DigniCap Delta on the market using the leasing business model. So far in 2022 the Company has continuously focused on reallocating weak utilized machines in some facilities to higher usage facilities with increasing demand. This enables the Company to reach more patients and improve patient outcomes and thereby achieve higher growth. Reallocation of devices to optimize utilization will continue as part of normal business operations as the market develops.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate balance effects are recognized in the income statement under other operating income and in other operating expenses. In the third quarter 2022 net exchange rate effects amounted to 3 337 TSEK (-20).

Operating Expenses and Operating Result

Operating expenses decreased during the quarter compared to the same period last year by 2 929 TSEK and

amounted to -15 518 TSEK (-18 447). The lower cost level in 2022 is primarily due to increased operational efficiency and normalized activities in Quality and Regulatory Affairs.

We are increasing activities supporting sales growth and consequently travel and marketing costs are expected to increase.

Depreciation and amortization in the Group amounted to -3 504 TSEK (-3 173) and remains largely unchanged.

The operating result after depreciation for the Group was for the second quarter -3 623 TSEK (-13 593).

Financial net

The financial net was -37 TSEK (-323), affected positively by exchange gains on bank accounts.

Employees

At the close of the period the Company had 25 (28) employees.

Cash Flow and Financial Position

Consolidated cash flow from operating activities during the quarter was -2 092 TSEK (-8 888), representing a significant improvement from previous quarters. Total cash flow for the period was -804 TSEK (-14 440), including utilization of the remaining 5 MSEK in credit facility from Agarthia. Cash and cash equivalents at the end of the quarter amounted to 6 737 TSEK (21 047).

Board and Management are continuously monitoring the financial position of the Company and are of the opinion that current business plans combined with the direct share issue performed in October are sufficient financial resources to cover working capital needs for the coming 12-month period.

CAPEX

Capex amounted to 1 351 TSEK (4 526) in the quarter.

DIGNITANA PARENT COMPANY

Revenues

Total revenues in the third quarter were 5 540 TSEK (1 393), of that other income was 3 003 TSEK (0) and is mainly attributable to exchange rate effects.

Operating Expenses and Operating Result

Operating expenses decreased during the quarter

compared to the same period last year by 4 899 TSEK and amounted to -4 716 TSEK (-9 615).

The operating result was -824 TSEK (-13 580) and net result for the period was -439 TSEK (-13 600).

The Parent company expenses, as well as revenues, are highly influenced by the timing of intercompany charges without effects on the group level.

The share

Dignitana has been listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap September 30	346 MSEK
Number of shareholders, approximately	2 439
Share price September 30	5.32 SEK
Number of shares traded during the quarter	1 857 819
Number of shares outstanding September 30	65 059 155
Registered share capital	6 505 916 SEK
Par value	0.1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and in February 2020 an extraordinary general meeting was held where a decision was taken to issue a maximum of 2 500 000 employee warrants to key employees of the Company. The period for exercising the employee stock warrants will run from 1 March 2023 to 31 March 2023. The employee warrants were granted gratuitously and yearly costs of 960 TSEK are booked continuously.



Largest Shareholders

30 SEPTEMBER 2022	HOLDINGS	PERCENT
AGARTHA AB	17 700 000	27,21%
SWEDBANK ROBUR MICROCAP	5 000 000	7,69%
AVANZA PENSION	4 684 539	7,20%
CBLDN-UBS FINANCIAL SERVICES INC.	4 189 739	6,44%
HANDELSBANKEN MICROCAP SVERIGE	3 000 000	4,61%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA	2 601 835	4,00%
FE SMÅBOLAG SVERIGE	1 800 000	2,77%
TECHNOBIS AB	1 790 593	2,75%
POURSAMAD, AMIR	1 445 124	2,22%
RÜLF, SEMMY	1 015 058	1,56%
TOTAL	43 226 888	66,44%
OTHER SHAREHOLDERS	21 832 267	33,56%
TOTAL	65 059 155	100,00%

Source: Euroclear



Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment methods, distributors and manufacturers, profitability and future capital requirements, political risk, geopolitical risks, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 in the spring of 2020 has affected the Company's opportunities to reach customers but also customers' ability to offer scalp cooling as a form of treatment. The Company has therefore been impacted financially, although it is not possible to make a full assessment.

Risks related to the Russian invasion of Ukraine

The company's assessment is that the ongoing military conflict in Ukraine, should not have any immediate significant effect on the operations. Indirect effects such as increases in energy costs and transportation, increased lead time of components and general cost increases could have some impact on the operations but are deemed as manageable. If the conflict spreads to more territories, this assessment could change. USA is the group's primary market from a sales and supply perspective.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2021 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements." Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc. and Dignitana S.r.l.

This interim report is prepared in accordance with Swedish GAAP, BFNR 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2021.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2021 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

This Interim Report has not been reviewed by the Group's Auditors.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 17 November 2022

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Deputy Chairman of the Board

Richard Dilorio
Board member

Lina Karlsson
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

Income Statement – Dignitana Group, TSEK

DIGNITANA GROUP	Q3 2022	Q3 2021	Q1-Q3 2022	Q1-Q3 2021	Full year 2021
Operating Income					
Net sales	18 602	13 657	52 750	40 860	57 073
Other operating income	3 049	66	9 678	4 194	5 303
Total Operating Income	21 651	13 723	62 428	45 054	62 376
Operating expense					
Goods for Resale	-6 252	-5 696	-17 787	-15 657	-20 711
Operating expense	-6 409	-5 440	-20 556	-21 818	-30 053
Personnel expense	-9 074	-7 734	-23 204	-22 285	-30 386
Depreciation and amortization of tangible and intangible assets	-3 504	-3 173	-10 122	-9 451	-12 737
Other operating expenses	-35	-5 273	-446	-5 980	-10 043
	-25 274	-27 316	-72 115	-75 191	-103 930
Operating profit (loss)	-3 623	-13 593	-9 687	-30 137	-41 554
Result from financial investments					
Other Interest income and similar items	345	14	601	93	118
Interest expenses and similar items	-382	-337	-1 314	-1 196	-1 640
	-37	-323	-713	-1 103	-1 522
Profit after financial items	-3 660	-13 916	-10 400	-31 240	-43 076
Profit before tax	-3 660	-13 916	-10 400	-31 240	-43 076
Tax on profit for the period	0	0	0	0	0
Results for the Period	-3 660	-13 916	-10 400	-31 240	-43 086
Average number of shares before and after dilution	65 059 155	65 059 155	65 059 155	65 059 155	65 059 155
Earnings per share before and after dilution, SEK	-0,06	-0,21	-0,16	-0,48	-0,66

Balance Sheet – Dignitana Group, TSEK

DIGNITANA GROUP	2022-09-30 2022	2021-09-30 2021	2021-12-31 2021
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	7 841	12 421	11 189
	7 841	12 421	11 189
Tangible assets			
Equipment, tools and installations	273	212	187
Machinery and other technical facilities	30 634	31 101	30 104
	30 907	31 313	30 291
Total Fixed Assets	38 748	43 734	41 480
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	8 078	7 741	7 120
	8 078	7 741	7 120
Current Receivables			
Accounts Receivable	7 431	5 711	5 103
Current Tax Assets	106	102	66
Other Current Receivables	588	933	862
Prepaid expenses and accrued income	2 440	1 355	2 222
	10 565	8 101	8 253
Cash and Bank Balances	6 737	21 047	14 501
Total Current Assets	25 380	36 889	29 874
Total Assets	64 128	80 623	71 354
EQUITY AND LIABILITIES			
Equity			
Share Capital	6 506	6 506	6 506
Unregistered share capital	0	0	0
Ongoing new issue	0	0	0
Other contributed capital	222 989	222 692	222 692
Other equity including profit for the year	-216 750	-184 801	-198 012
Total Equity	12 745	44 397	31 186
Provisions			
Other provisions	6	18	69
	6	18	69
Long Term Liabilities			
Other long term liabilities	11 824	11 014	15 828
Total Long Term Liabilities	11 824	11 014	15 828
Current Liabilities			
Liabilities to credit institutions	10 097	4 708	7 762
Accounts payable	7 349	10 518	6 234
Other current liabilities	11 151	870	761
Accrued expenses and deferred income	10 956	9 098	9 514
Total current liabilities	39 553	25 194	24 271
Total liabilities	51 377	36 208	40 099
Total Equity and Liabilities	64 128	80 623	71 354

Changes in Equity – Dignitana Group, TSEK

	Share capital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2021	6 506	222 692	-151 562	77 636
Net loss for the year			-43 086	-43 086
Option program 2021			960	960
Change in translation difference relating to subsidiaries			-4 324	-4 324
Closing equity on 12/31/2021	6 506	222 692	-198 012	31 186
Net loss for the period			-10 400	-10 400
Share warrants		378		378
Option program 2022			720	720
Issue costs		-81		-81
Change in translation difference relating to subsidiaries			-9 058	-9 058
Closing equity on 09/30/2022	6 506	222 989	-216 750	12 745

Statement of Cash Flows – Dignitana Group, TSEK

DIGNITANA GROUP	Q3 2022	Q3 2021	Q1-Q3 2022	Q1-Q3 2021	Full year 2021
Operating activities					
Profit after financial investments	-3 660	-13 916	-10 400	-31 240	-43 076
Adjustments for items not affecting cash flows, etc	125	3 584	888	7 564	12 288
Tax paid	-18	-15	-42	-105	-80
Cash flow from operating activities before changes in working capital	-3 553	-10 347	-9 554	-23 781	-30 868
Cash flow from changes in working capital					
Change in inventories	-838	-960	-492	-251	-467
Change in other current receivables	2 238	589	-1 091	413	422
Change in other current liabilities	61	1 830	458	-8 374	-12 960
Cash flows from operating activities	-2 092	-8 888	-10 679	-31 993	-43 873
Investing activities					
Investments in intangible assets	0	0	0	0	0
Proceeds from sale of intangible assets	0	0	0	0	0
Investments in tangible assets	-1 351	-4 526	-1 823	-9 433	-10 556
Cash flows from investing activities	-1 351	-4 526	-1 823	-9 433	-10 556
Financing activities					
New share issue	0	0	0	0	0
Issue expenses	-81	0	-81	0	0
Options issued	0	0	378	0	0
New loans	5 204	0	10 204	0	0
Repaid loans	0	0	0	-20 000	-20 000
Changes in long and short term liabilities to credit institutions	-2 484	-1 026	-6 523	5 201	12 679
Cash flow from financial activities	2 639	-1 026	3 978	-14 799	-7 321
Cash flow for the period	-804	-14 440	-8 524	-56 225	-61 750
Cash and cash equivalents at beginning of period					
Cash and cash equivalents at beginning of period	7 312	36 333	14 501	78 770	78 770
Exchange-rate differences in cash and cash equivalents					
Exchange-rate differences in cash and cash equivalents	229	-846	760	-1 497	-2 519
Cash and cash equivalents at end of period	6 737	21 047	6 737	21 047	14 501

Income Statement – Dignitana AB, Parent Company, TSEK

DIGNITANA GROUP	Q3 2022	Q3 2021	Q1-Q3 2022	Q1-Q3 2021	Full year 2021
Operating Income					
Net sales	2 537	1 393	8 351	20 053	37 743
Other operating income	3 003	0	9 394	988	1 940
Total Operating Income	5 540	1 393	17 745	21 041	39 683
Operating expense					
Goods for Resale	-518	-2 243	-2 714	-6 655	-7 179
Operating expense	-1 699	-5 537	-8 008	-12 651	-41 512
Personnel expense	-2 920	-2 984	-6 061	-10 620	-5 367
Depreciation and amortization of tangible and intangible assets	-1 130	-3 115	-5 515	-9 283	-12 517
Other operating expenses	-97	-1 094	-272	-1 689	-3 430
	-6 364	-14 973	-22 570	-40 898	-70 005
Operating profit (loss)	-824	-13 580	-4 825	-19 857	-30 322
Result from financial investments					
Other Interest income and similar items	345	15	601	94	118
Interest expenses and similar items	40	-35	-16	-459	-473
	385	-20	585	-365	-355
Profit after financial items	-439	-13 600	-4 240	-20 222	-30 677
Profit before tax	-439	-13 600	-4 240	-20 222	-30 677
Tax on profit for the period	0	0	0	0	0
Results for the Period	-439	-13 600	-4 240	-20 222	-30 677

Balance Sheet – Dignitana AB, Parent Company, TSEK

DIGNITANA AB, PARENT COMPANY	2022-09-30 2022	2021-09-30 2021	2021-12-31 2021
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	7 815	12 396	11 165
	7 815	12 396	11 165
Tangible assets			
Equipment, tools and installations	0	0	0
Machinery and other technical facilities	127	31 101	30 104
	127	31 101	30 104
Financial assets			
Participations in group companies	66 198	522	522
Receivable from group companies	7 230	440	452
	73 428	962	974
Total Fixed Assets	81 370	44 459	42 243
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	5 320	5 026	5 289
	5 320	5 026	5 289
Current Receivables			
Accounts Receivable	1 367	1 366	1 927
Receivables from group companies	1 534	30 276	26 992
Current Tax Assets	106	102	117
Other Current Receivables	449	836	772
Prepaid expenses and accrued income	503	483	854
	3 959	33 063	30 662
Cash and Bank Balances	3 212	16 014	9 239
Total Current Assets	12 491	54 103	45 190
Total Assets	93 861	98 562	87 433
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share Capital	6 506	6 506	6 506
Unregistered share capital	0	0	0
Fund for development expenses	7 816	12 281	11 165
	14 322	18 787	17 671
Non-restricted equity			
Share premium reserves	222 989	222 692	222 692
Other non-restricted equity	-156 770	-130 559	-129 442
Results for the period	-4 240	-20 222	-30 677
	61 979	71 911	62 573
Total Equity	76 301	90 698	80 244
Current Liabilities			
Accounts payable	1 025	3 247	2 124
Current payable to group company	361	0	0
Other current liabilities	10 716	130	129
Accrued expenses and deferred income	5 458	4 487	4 936
Total current liabilities	17 560	7 864	7 189
Total liabilities	17 560	7 864	7 189
Total Equity and Liabilities	93 861	98 562	87 433

Financial calendar

16 February 2023	2022 Year End Report
25 May 2023	Q1 Report
25 May 2023	Annual General Meeting
17 August 2023	Q2 Report
16 November 2023	Q3 Report
15 February 2024	2023 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.com

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se